13 results match your criteria: "CM2R (Memory Resource and Research Centre)[Affiliation]"
Alzheimers Res Ther
July 2024
Geriatrics Department, University Hospital of Strasbourg, CM2R (Memory Resource and Research Centre), Strasbourg, France.
Background: Dementia with Lewy Bodies (DLB) is responsible for cognitive-behavioural disorders but also for gait disorders. The latter are thought to be related to parkinsonism, but the neural bases of these disorders are not well known, especially in the early stages. The aim of this study was to investigate by volumetric Magnetic Resonance Imaging the neuronal basis of gait disorders in DLB patients, compared to Healthy Elderly Controls and Alzheimer's Disease patients.
View Article and Find Full Text PDFAlzheimers Res Ther
July 2024
AP-HP Nord, Cognitive Neurology Center Hôpital Lariboisière-Fernand Widal, Université Paris Cité, 200 rue du Faubourg Saint-Denis, Paris, 75010, France.
Front Aging Neurosci
September 2022
ICube Laboratory and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, Université de Strasbourg, Strasbourg, France.
Narrative discourse (ND) comprehension is a complex task that implies not only linguistic abilities but also other cognitive abilities, including efficient executive functioning. An executive dysfunction has been described in dementia with Lewy bodies (DLB) from the early stage. Here, we question the link between executive dysfunction in DLB and narrative comprehension.
View Article and Find Full Text PDFAlzheimers Res Ther
July 2022
CHU de Bordeaux, Pôle de santé publique, Bordeaux, France.
Background: Isolated subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are the prodromal phases of dementia with Lewy bodies (DLB). MEMENTO is a nationwide study of patients with SCI and MCI with clinic, neuropsychology, biology, and brain imaging data. We aimed to compare SCI and MCI patients with symptoms of prodromal DLB to others in this study at baseline.
View Article and Find Full Text PDFFront Neurol
April 2022
Centre de Recherche Cerveau & Cognition (CerCo), UMR 5549, CNRS-UPS, Toulouse, France.
The observation that a pathophysiological link might exist between Alzheimer's disease (AD) and epilepsy dates back to the identification of the first cases of the pathology itself and is now strongly supported by an ever-increasing mountain of literature. An overwhelming majority of data suggests not only a higher prevalence of epilepsy in Alzheimer's disease compared to healthy aging, but also that AD patients with a comorbid epileptic syndrome, even subclinical, have a steeper cognitive decline. Moreover, clinical and preclinical investigations have revealed a marked sleep-related increase in the frequency of epileptic activities.
View Article and Find Full Text PDFMov Disord
March 2022
University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR U1219, Bordeaux, France.
α-synucleinopathies, encompassing Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, are devastating neurodegenerative diseases for which available therapeutic options are scarce, mostly because of our limited understanding of their pathophysiology. Although these pathologies are attributed to an intracellular accumulation of the α-synuclein protein in the nervous system with subsequent neuronal loss, the trigger(s) of this accumulation is/are not clearly identified. Among the existing hypotheses, interest in the hypothesis advocating the involvement of infectious agents in the onset of these diseases is renewed.
View Article and Find Full Text PDFDrugs Aging
March 2021
Clinical Neuropsychology Unit, Neurology Department, CM2R (Memory Resource and Research Centre), University Hospital of Strasbourg, Strasbourg, France.
The numbers of patients with dementia and patients with epilepsy are increasing in the global population. In fact, these two conditions are related, and it is estimated that at least 5-10% of seizures or epilepsy in older individuals (aged > 60 years) are caused by a neurodegenerative dementia. In the vast majority, one of the four following diseases is involved: Alzheimer's disease, Lewy body dementia, frontotemporal dementia, or vascular dementia.
View Article and Find Full Text PDFAnn Neurol
February 2021
Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.
Objective: Isolated (or idiopathic) rapid eye movement sleep behavior disorder (iRBD) is associated with dementia with Lewy bodies (DLB) and Parkinson's disease (PD). Biomarkers are lacking to predict conversion to a dementia or a motor-first phenotype. Here, we aimed at identifying a brain-clinical signature that predicts dementia in iRBD.
View Article and Find Full Text PDFBrain
December 2020
Laboratory of Engineering, Informatics and Imaging (ICube), Integrative multimodal imaging in healthcare (IMIS), UMR 7357, University of Strasbourg, 67000 Strasbourg, France.
In Alzheimer's disease, the tauopathy is known as a major mechanism responsible for the development of cognitive deficits. Early biomarkers of such affectations for diagnosis/stratification are crucial in Alzheimer's disease research, and brain connectome studies increasingly show their potential establishing pathology fingerprints at the network level. In this context, we conducted an in vivo multimodal MRI study on young Thy-Tau22 transgenic mice expressing tauopathy, performing resting state functional MRI and structural brain imaging to identify early connectome signatures of the pathology, relating with histological and behavioural investigations.
View Article and Find Full Text PDFPsychogeriatrics
November 2020
Clinical Neuropsychology Unit, Neurology Department, University Hospital of Strasbourg, CM2R (Memory Resource and Research Centre), Strasbourg, France.
Seizure
October 2020
University of Strasbourg, CNRS, ICube laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), team IMIS, Strasbourg, France; University Hospital of Strasbourg, CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, Strasbourg, France.
J Neurol Neurosurg Psychiatry
September 2020
Institut de Biologie Moléculaire des Plantes, Plant Imaging and Mass Spectrometry (PIMS), CNRS, University of Strasbourg, Strasbourg, France.
Background: In neurodegenerative diseases, alongside genetic factors, the possible intervention of environmental factors in the pathogenesis is increasingly being considered. In particular, recent evidence suggests the intervention of a pesticide-like xenobiotic in the initiation of disease with Lewy bodies (DLB).
Objectives: To test for the presence of pesticides or other xenobiotics in the cerebrospinal fluid (CSF) of patients with DLB.
Expert Opin Pharmacother
March 2020
Neurology Department, Clinical Neuropsychology Unit, University Hospital of Strasbourg, CM2R (Memory Resource and Research Centre), Strasbourg, France.